DFTX’s latest Panorama Phase 3 GAD data hit primary and key secondary endpoints, with a 5.1-point placebo-adjusted anxiety-score improvement and effects visible by Day 2 [#31, #33]. The stronger why-now is that the third Phase 3 win moves DT120 toward an FDA submission, with analysts describing a clearer regulatory pathway and filings for two indications [#7, #28, #42].

ENVX sold off hard after Raj Talluri resigned, but the company reaffirmed Q3 guidance, kept customer programs intact, and moved T.J. Rodgers plus CFO Ryan Benton into interim leadership while a full CEO search runs [#3, #5, #6]. The operating story has not broken: lead smartphone cells cleared 1,000+ cycles, Q2 revenue beat estimates, and the pipeline expanded sharply, making the leadership-discount look potentially overdone [#2, #15, #1]. A credible permanent CEO announcement is the near-term re-rating trigger, with prior operator appointments viewed as tape-moving events [#8].

GLUE’s reversal has a company-specific why-now: H2 2026 includes IND submissions for next-gen NEK7 and cyclin E1 degraders plus a GFORCE-1 Phase 1 readout for MRT-8102 [#2, #6]. The stock was hit by a negative ZEUS read-through, but program-specific updates indicate MRT-8102 studies continue and multiple Phase 2 starts remain planned in H2 2026 [#14, #24].

FRMI has already de-risked the story with TensorWave as Project Matador’s first customer, a 15-year 222MW lease tied to roughly $6.5B in contracted revenue and possible expansion to 650MW+ [#3, #10, #14]. The why-now setup is the pending Tier 1 guarantor announcement, which bulls frame as capable of driving a 30%+ spike while AI power scarcity keeps the strategic demand case intact [#7, #13].

Olin is trading near $20 while the market is described as ignoring robust free-cash-flow generation and the strategic value of the Huntsman deal [#3]. The pending vote on the 0.5476x stock merger creates a discrete why-now window, while recent analyst target cuts mark a sentiment reset rather than a new bull case [#17, #19].